SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 9.6% Stake in Crinetics Pharmaceuticals

Sentiment:

Beneficial Ownership Disclosure


FMR LLC and its Chief Executive Officer, Abigail P. Johnson, have reported a beneficial ownership of 9.6% of Crinetics Pharmaceuticals Inc.'s common stock as of December 31, 2024.

Summary

  • FMR LLC and Abigail P. Johnson jointly reported beneficial ownership of 8,904,085.92 shares of Crinetics Pharmaceuticals Inc. common stock.
  • This represents 9.6% of the total outstanding common stock of Crinetics Pharmaceuticals Inc.
  • The filing is an Amendment No. 1 to Schedule 13G, indicating an update to a previously reported stake.
  • FMR LLC, a parent holding company, holds sole voting power over 8,901,329 shares and sole dispositive power over 8,904,085.92 shares.
  • Abigail P. Johnson, as an individual, shares dispositive power over 8,904,085.92 shares, reflecting her control relationship with FMR LLC.
  • The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Crinetics Pharmaceuticals Inc.
  • Several FMR LLC subsidiaries, including Fidelity Management & Research Company LLC, are identified as entities that beneficially own shares, with Fidelity Management & Research Company LLC owning 5% or greater.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory filing disclosing beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment towards the issuer beyond the mere existence of a significant institutional stake.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of a significant ownership stake by a major asset manager in a pharmaceutical company. It reflects FMR LLC's investment strategy within the healthcare or biotechnology sector.

Stakeholder Impact

  • Provides transparency to existing and potential shareholders regarding a significant institutional ownership stake.

Key Dates

DateDescription
2023-01-03Effective date of Power of Attorney for FMR LLC.
2023-01-10Date of Schedule 13G filing by FMR LLC where Power of Attorney (accession number -23-000003) was incorporated by reference.
2023-01-26Effective date of Power of Attorney for Abigail P. Johnson.
2023-01-31Date of Schedule 13G filing by FMR LLC where Abigail P. Johnson's Power of Attorney (accession number -23-000038) was incorporated by reference.
2024-12-31Date of event which requires filing of this statement (reporting date for ownership).
2025-02-06Date of filing of this Schedule 13G Amendment No. 1.

Keywords

Crinetics Pharmaceuticals Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Pharmaceuticals, Biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.